Mesenchymal Stem Cell Preparation and Transfection‐free Ferumoxytol Labeling for MRI Cell Tracking

Citations Over Time

Abstract

Mesenchymal stem cells (MSCs) are multipotent cells and are the most widely studied cell type for stem cell therapies. In vivo cell tracking of MSCs labeled with an FDA-approved superparamagnetic iron-oxide (SPIO) particle by magnetic resonance imaging (MRI) provides essential information, e.g., MSC engraftment, survival, and fate, thus improving cell therapy accuracy. However, current methodology for labeling MSCs with Ferumoxytol (Feraheme® ), the only FDA-approved SPIO particle, needs transfection agents. This unit describes a new "bio-mimicry" protocol to prepare more native MSCs by using more "in vivo environment" of MSCs, so that the phagocytic activity of cultured MSCs is restored and expanded MSCs can be labeled with Ferumoxytol, without the need for transfection agents and/or electroporation. Moreover, MSCs re-size to a more native size, reducing from 32.0 to 19.5 μm. The MSCs prepared from this protocol retain more native properties and would be useful for biomedical applications and MSC-tracking studies by MRI. © 2017 by John Wiley & Sons, Inc.

Related Papers

• → Mesenchymal Stem Cell Preparation and Transfection‐free Ferumoxytol Labeling for MRI Cell Tracking(2017)10 cited
• → Analysis of approaches to increase the efficacy of cell therapy based on mesenchymal stromal cells(2021)2 cited
• → Placenta-derived mesenchymal stem cells for allogenic cardiac cell therapy(2012)1 cited
• → GW25-e0810 Intravenous ferumoxytol before mesenchymal stem cell harvest: a new method for tracking stem cell with MR imaging in cell therapy for myocardial infarction(2014)
• → Immunomodulatory characterization of an umbilical cord-derived mesenchymal stromal cells (UC-MSCs)-based cell therapy(2021)